Bio News

U.S.-based Agenus reported a 48% estimated 3-year survival rate in a phase 1b trial involving 35 patients with recurrent ovarian cancer.
Patients had received a median of 4 prior lines of treatment, and three-quarters had platinum-resistant or platinum-refractory disease.
Agenus said the combination of botensilimab and balstilimab could provide lasting benefit to patients with limited treatment options.

Biobook Team
biobookmedia@biobook.co.krCosentyx Approved by FDA for 11th Indication: Polymyalgia Rheumatica
Delonix and Singapore’s A*STAR IDL to Collaborate on Vaccine Against Drug-Resistant Klebsiella pneumoniae
Brazilian Health Regulatory Agency Approves Oral Plaque Psoriasis Treatment Icotyde
Medtronic to Acquire Contego Medical for $380 Million
Brazilian Health Regulatory Agency Approves Botox for Masseter Muscle Prominence
Roche’s oral SERD Itovebi wins FDA approval, cutting risk of progression by 62%